FNT
TEVA icon

First National Trust’s Teva Pharmaceuticals TEVA Stock Holding History

First National Trust’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,878
Closed -$295K – 333
2017
Q2 		$295K Buy
8,878
+555
+7% +$17.2K 0.04% 282
2017
Q1 		$267K Sell
8,323
-1,875
-18% -$64K 0.03% 280
2016
Q4 		$370K Sell
10,198
-1,191
-10% -$47.6K 0.05% 239
2016
Q3 		$524K Sell
11,389
-424
-4% -$22.1K 0.08% 197
2016
Q2 		$593K Sell
11,813
-657
-5% -$35K 0.09% 186
2016
Q1 		$667K Buy
12,470
+451
+4% +$26.5K 0.1% 173
2015
Q4 		$789K Buy
12,019
+1,320
+12% +$81.6K 0.12% 160
2015
Q3 		$604K Buy
10,699
+793
+8% +$51.4K 0.1% 185
2015
Q2 		$585K Buy
9,906
+305
+3% +$18.8K 0.09% 185
2015
Q1 		$598K Buy
9,601
+702
+8% +$40.8K 0.1% 173
2014
Q4 		$512K Buy
8,899
+680
+8% +$37.9K 0.09% 178
2014
Q3 		$442K Sell
8,219
-1,844
-18% -$97.7K 0.08% 184
2014
Q2 		$527K Sell
10,063
-2,739
-21% -$140K 0.1% 165
2014
Q1 		$676K Sell
12,802
-434
-3% -$20.1K 0.12% 143
2013
Q4 		$530K Sell
13,236
-2,286
-15% -$90K 0.1% 162
2013
Q3 		$587K Sell
15,522
-4,053
-21% -$158K 0.12% 151
2013
Q2 		$768K Buy
+19,575
New +$762K 0.16% 129

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

First National Trust's TEVA Position: Q3 2017 in Review

First National Trust sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 8,878 shares — an estimated $295K sold.

First National Trust first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $789K in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • First National Trust reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • First National Trust sold 8,878 Teva Pharmaceuticals shares in Q3 2017, an estimated $295K.
  • First National Trust first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • First National Trust's Teva Pharmaceuticals position peaked at $789K in Q4 2015.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on First National Trust's 13F filing for Q3 2017, filed 6 Nov 2017.